Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.PRA inaugurates new office in Romania
PRA is a provider of personalized service customized to the requirements of each study. The company is conducting trials in Romania since 2006. PRA Clinical Operations in Europe,
PRA is a provider of personalized service customized to the requirements of each study. The company is conducting trials in Romania since 2006. PRA Clinical Operations in Europe,
Centricity Business 5.0 improves ability to meet risks of growing self-pay patient population by reducing human touch across the patient access and revenue cycle processes. The application provides
The lawsuit alleges that the companies failed to warn the consumers of Actos regarding the increased risk of bladder cancer associated with pioglitazone, sold under the brand name
The tie up allows Rechon to manufacture and market Zolpimist, an oral spray formulation of zolpidem tartrate, outside North America. As per the terms of the agreement, NovaDel
The drug is used for the reduction of rate of thrombotic cardiovascular (CV) events in patients suffering from acute coronary syndrome (ACS). Brilinta has demonstrated reduction in the
The drug has been approved for use in conjunction with two different hepatitis C drugs, pegylated-interferon and ribavirin. The combined dosage is indicated for the patients who are
Previously, Cosby worked as the president and chief operating officer of Macy’s East, and senior vice president for Property Development of Federated Department Stores. CVS Caremark president and
Affymetrix executive vice president, general counsel and secretary Rick Runkel said they are pleased that the Federal Circuit has affirmed the District Court’s prior rulings that Affymetrix does
The company has posted a net income of $3.35m for the second quarter of 2011, compared to $ 4.14m for the same period in 2010. For the six
The Phase I trial conducted in healthy volunteers and a Phase IIa clinical trial in stable heart failure patients met the safety, tolerability, pharmacokinetics and pharmacodynamic effects of